Daré Bioscience reports third quarter 2026 financial results and highlights commercial execution and pipeline advancement
DARE•Daré Bioscience expects to begin recording revenue from Dare to Play sildenafil cream sales in Q4 2026, and targets revenue from its Dare to Reclaim ring in 2027.
1. Revenue outlook
Daré Bioscience said it expects to begin recording revenue from sales of Dare to Play sildenafil cream in Q4 2026. Revenue from its Dare to Reclaim estradiol and progesterone intravaginal ring is targeted to begin in 2027. The company said it continues to pursue additional grant funding to support its programs and expand development opportunities.




